Finally and importantly, we have shown that nMRTF BCC cells exist as a distinct cell state, which can be effectively targeted with small-molecule MRTF and AP-1 inhibitors, using LYPD3, TACSTD2, and LY6D as prognostic markers. Here, LY6D is linked to skin basal cell carcinoma.